immune induction after irradiation. Biochim Biophys Acta 2016;1865:168–175.
65Wunderlich R, et al: Low and moderate doses of ionizing radiation up to 2 Gy modulate transmigration and chemotaxis of activated macrophages, provoke an anti-inflammatory cytokine milieu, but do not impact upon viability and phagocytic function. Clin Exp Immunol 2015;179:50–61.
66Twyman-Saint VC, et al: Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer. Nature 2015;520:373–377.
67Belcaid Z, et al: Focal radiation therapy combined with 4-1BB activation and CTLA-4 blockade yields long-term survival and a protective antigen-specific memory response in a murine glioma model. PLoS One 2014;9:e101764.
68Demaria S, et al: Immune-mediated inhibition of metastases after treatment with local radiation and CTLA-4 blockade in a mouse model of breast cancer. Clin Cancer Res 2005;11:728–734.
69Dewan MZ, et al: Fractionated but not single-dose radiotherapy induces an immune-mediated abscopal effect when combined with anti-CTLA-4 antibody. Clin Cancer Res 2009;15:5379–5388.
70Sharabi AB, et al: Stereotactic radiation therapy augments antigen-specific PD-1-mediated antitumor immune responses via cross-presentation of tumor antigen. Cancer Immunol Res 2015;3:345–355.
71Zeng J, et al: Anti-PD-1 blockade and stereotactic radiation produce long-term survival in mice with intracranial gliomas. Int J Radiat Oncol Biol Phys 2013;86:343–349.
72Grimaldi AM, et al: Abscopal effects of radiotherapy on advanced melanoma patients who progressed after ipilimumab immunotherapy. Oncoimmunology 2014;3:e28780.
73Kwon ED, et al: Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial. Lancet Oncol 2014;15:700–712.
74Trump D: Commentary on: “Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial.” Urol Oncol 2016;34:249–250.
75Vanpouille-Box C, et al: In situ vaccination by radiotherapy to improve responses to anti-CTLA-4 treatment. Vaccine 2015;33:7415–7422.
76Garnett-Benson C, Hodge JW, Gameiro SR: Combination regimens of radiation therapy and therapeutic cancer vaccines: mechanisms and opportunities. Semin Radiat Oncol 2015;25:46–53.
77Mondini M, et al: Synergy of radiotherapy and a cancer vaccine for the treatment of HPV-associated head and neck cancer. Mol Cancer Ther 2015;14:1336–1345.
78Fotin-Mleczek M, et al: mRNA-based vaccines synergize with radiation therapy to eradicate established tumors. Radiat Oncol 2014;9:180.
79Sebastian M, et al: Phase Ib study evaluating a self-adjuvanted mRNA cancer vaccine (RNActive®) combined with local radiation as consolidation and maintenance treatment for patients with stage IV non-small cell lung cancer. BMC Cancer 2014;14:748.
80Lechleider RJ, et al: Safety and immunologic response of a viral vaccine to prostate-specific antigen in combination with radiation therapy when metronomic-dose interleukin 2 is used as an adjuvant. Clin Cancer Res 2008;14:5284–5291.
81Kamrava M, et al: Long-term follow-up of prostate cancer patients treated with vaccine and definitive radiation therapy. Prostate Cancer Prostatic Dis 2012;15:289–295.
82Haji-Fatahaliha M, et al: CAR-modified T-cell therapy for cancer: an updated review. Artif Cells Nanomed Biotechnol 2016;44:1339–1349.
83Lameris R, et al: Bispecific antibody platforms for cancer immunotherapy. Crit Rev Oncol Hematol 2014;92:153–165.
84Weidle UH, Kontermann RE, Brinkmann U: Tumor-antigen-binding bispecific antibodies for cancer treatment. Semin Oncol 2014;41:653–660.
85Cartellieri M, et al: TCR/CD3 activation and co-stimulation combined in one T cell retargeting system improve anti-tumor immunity. Oncoimmunology 2013;2:e26770.
86Zegers CM, et al: Radiotherapy combined with the immunocytokine L19-IL2 provides long-lasting antitumor effects. Clin Cancer Res 2015;21:1151–1160.
87Rekers NH, et al: Long-lasting antitumor effects provided by radiotherapy combined with the immunocytokine L19-IL2. Oncoimmunology 2015;4:e1021541.
88Rekers NH, et al: Combination of radiotherapy with the immunocytokine L19-IL2: additive effect in a NK cell dependent tumour model. Radiother Oncol 2015;116:438–442.
89van den Heuvel MM, et al: NHS-IL2 combined with radiotherapy: preclinical rationale and phase Ib trial results in metastatic non-small cell lung cancer following first-line chemotherapy. J Transl Med 2015;13:32.
90Schilbach K, et al: Cancer-targeted IL-12 controls human rhabdomyosarcoma by senescence induction and myogenic differentiation. Oncoimmunology 2015;4:e1014760.
91Paoloni M, et al: Defining the pharmacodynamic profile and therapeutic index of NHS-IL12 immunocytokine in dogs with malignant melanoma. PLoS One 2015;10:e0129954.
92Eckert F, et al: Enhanced binding of necrosis-targeting immunocytokine NHS-IL12 after local tumour irradiation in murine xenograft models. Cancer Immunol Immunother 2016;65:1003–1013.
93Kang J, Demaria S, Formenti S: Current clinical trials testing the combination of immunotherapy with radiotherapy. J Immunother Cancer 2016;4:51.
94Kulzer L, et al: Norm- and hypo-fractionated radiotherapy is capable of activating human dendritic cells. J Immunotoxicol 2014;11:328–336.
95Gandhi